LBD 2.0 EP #1: Why Scientific Validity Isn't Enough

In this episode of Longevity by Design, host Renée Deehan, VP of Science & Artificial Intelligence is joined by co-host Will Dzierson, VP of Product & Design, both at InsideTracker to welcome the guest Derek Chiang, VP and Head of Computational Biology at Bayer Pharmaceuticals. Renée and Derek — former Berkeley classmates — reconnect to trace how the field of computational biology has evolved from data-starved beginnings into today's AI-driven drug discovery engine. Derek walks through what personalized medicine actually means at a molecular level, using cancer as a case study for how genomic "mistakes" can be matched to targeted therapies.

In this episode of Longevity by Design, host Renée Deehan, Senior VP of Science, AI & Product, is joined by Will Dzierson, VP of Product & Design, both with InsideTracker, to welcome Ohad Manor, VP of Computational and Precision Health at Thorne. Ohad brings a rare perspective, having traversed academic computational biology, personalized wellness at Arivale, cancer therapeutics and diagnostics, and now consumer precision health at Thorne. The thread connecting all of it: using computation to translate complex biology into something genuinely useful for people.

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Andrea Maier, Professor in Medicine and Director of the NUS Academy for Healthy Longevity at the National University of Singapore’s School of Medicine. They explore what the evidence shows on supplements, and why “test, then treat” beats guesswork.Andrea unpacks a review of over 5 million people: multivitamins may support memory and lower systolic blood pressure in some older or at-risk groups, but offer little for healthy adults. She also reports lab audits of Nicotinamide Mononucleotide (NMN) and urolithin A, in which many products fell short of the label claims.She then sorts buzzworthy compounds like alpha-ketoglutarate, spermidine, curcumin, and melatonin by mechanism, trial quality, and fit. Her rule stays simple: measure what you can, match the dose to the need, and track outcomes with walking speed, grip strength, steps, and wearable sleep data over time, not once. Guest-at-a-Glance💡 Name: Dr. Andrea Maier💡 What she does: Professor in Medicine, Healthy Ageing and Dementia Research, and Director of the NUS Academy for Healthy Longevity💡 Company: the National University of Singapore’s School of Medicine💡 Noteworthy: She runs human trials on supplements and aging, audits label accuracy in the lab, and pushes a “measure first” approach using biomarkers, wearables, and simple strength tests.💡 Where to find her: https://www.linkedin.com/in/andreamaierprof💡 Guest Company Website: https://discovery.nus.edu.sg/19564-andrea-britta-maier  Episode highlights:[00:00:00]: Introduction[00:01:02]: Overview of Evidence-Based Clinical Practice[00:02:16]: Multivitamins and Minerals: Usage and Population Trends[00:04:08]: Systematic Review Findings on Multivitamins and Cognitive Health[00:05:44]: Who Benefits Most from Multivitamin Supplementation[00:06:57]: Personalized Nutrition and the Case for Targeted Supplementation[00:08:21]: Ongoing Clinical Trials on Multivitamins and Biological Age[00:09:19]: Supplement Quality: Label Claims Versus Actual Content[00:12:14]: Navigating Supplement Quality and Consumer Guidance[00:14:53]: Novel Longevity Compounds: Alpha-Ketoglutarate[00:17:47]: Alpha-Ketoglutarate: Human Evidence and Population Focus[00:18:29]: Spermidine: Dietary Sources and Human Evidence[00:21:25]: Curcumin: Mechanisms, Evidence, and Target Populations[00:24:54]: Evaluating Supplements for Clinical Use[00:27:08]: Scientific Approach to Supplement Research[00:29:26]: The Role of Independent Research in Supplement Evaluation[00:32:37]: Melatonin: Sleep, Jet Lag, and Circadian Rhythm[00:37:25]: Practical Melatonin Use for Travel and Sleep Optimization[00:41:05]: Digital Biomarkers: Definition and Emerging Role[00:45:54]: Integrating Digital Biomarkers into Healthcare Practice[00:49:05]: Physical Function Tests: Grip Strength and Sit-to-Stand[00:59:48]: NAD Precursors: NMN, NR, and Human Trials[01:05:23]: NAD Testing: Current Landscape and Future Directions[01:07:24]: Final Takeaways and Closing Remarks   For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Uri Alon, Professor at Weizmann Institute of Science. They explore a systems view of aging that treats longevity as a solvable model, not a grab bag of disconnected theories.Uri explains aging with a simple story: houses make garbage, trucks remove it, and the village has a threshold for how much damage it can handle. In the body, “garbage” can include damaged and senescent cells, “trucks” can include immune cleanup, and “houses” can include long-lived cells and stem cells that drift over time. The model links this balance to death, disease, and steady decline, and it helps predict which interventions actually change it.They also revisit the role of genes. Uri argues that lifespan looks closer to 50% heritable today after correcting for early, non-aging deaths in older datasets. The rest comes from the environment and biological noise, which regular sleep may help reduce.Guest-at-a-Glance💡 Name: Dr. Uri Alon💡 What they do: Professor of Molecular Cell Biology and systems biology researcher💡 Company: Weizmann Institute of Science💡 Noteworthy: He developed the network motifs framework and uses simple models to explain aging as a balance between damage, cleanup capacity, and robustness thresholds.💡 Where to find him: https://www.linkedin.com/in/urialonw/  Episode highlights:[00:00:00]: Introduction[00:01:41]: Transition from Physics to Biology and Systems Thinking[00:03:06]: Systems Perspective vs. Traditional Biology[00:03:45]: Theoretical Models and Patterns in Aging[00:06:29]: Network Motifs and Biological Circuits[00:10:26]: Applying Systems Biology to Aging and Healthspan[00:12:27]: The Village Model: Framework for Understanding Aging[00:19:24]: Interventions: Exercise, Robustness, and Lifespan Limits[00:22:41]: Multi-level Modeling: From High-Level to Molecular Detail[00:23:56]: Centenarians, Genetic Variants, and Disease Resistance[00:25:26]: Menopause, Aging Genes, and Rare Variants[00:26:57]: Heritability of Lifespan: Revisiting Twin Studies[00:29:23]: Lifestyle, Genetics, and Diminishing Returns[00:33:23]: Biological Noise, Environment, and Variability[00:36:23]: Developmental Stochasticity and Lifespan Differences[00:38:20]: Future Impact of Medicine on Genetic Influence[00:40:36]: Polygenic Scores, Planning, and Public Perception[00:41:25]: Genetic Circuits and Longevity Pathways[00:44:22]: Epigenetic Reprogramming vs. Senolytics[00:47:16]: Technological Readiness and Combining Interventions[00:48:44]: Other Promising Interventions: Rapamycin, Engineering, and Targeted Approaches[00:51:24]: GLP-1, SGLT2 Inhibitors, and Robustness[00:53:01]: Vascular Health, Immune Function, and Lifespan Extension[00:56:28]: Quick Fire Round: Myths, Principles, and Predictors[00:59:04]: Key Takeaways: Systems View and the Equation of Aging[01:02:07]: Closing Remarks and Farewell   For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast 

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Paola Sebastiani, Professor of Biostatistics at Tufts Clinical and Translational Science Institute. They explore what centenarians reveal about reaching 100, and why there’s no single longevity gene.Paola explains that studies keep finding many small genetic effects, which makes polygenic risk scores hard to use for personal prediction. She says progress depends on bigger cohorts and new analyses that include structural DNA changes and mitochondrial DNA. She also grounds the hype: for people born in 1900, only 0.2% of men and about 1% of women reached 100.Healthspan sits at the center of the story. Paola ties exceptional aging to delayed disease, lower inflammation, and biomarker profiles that stay more youthful. She highlights diet as a realistic lever, with centenarians showing stable, balanced eating, steadier protein intake, and metabolite signals linked to vegetables and dark chocolate.  Guest-at-a-glance💡 Name: Dr. Paola Sebastiani💡 What they do: Professor of Biostatistics💡 Company: Tufts Clinical and Translational Science Institute💡 Noteworthy: She analyzes genetic, proteomic, and metabolomic data from centenarians to map longevity signatures, with a focus on APOE, inflammation, and delayed onset of age-related disease.💡 Where to find her: https://www.linkedin.com/in/paola-sebastiani-5973a646 Episode highlights:[00:00:00]: Introduction[00:01:17]: Genetics and Longevity—Centenarian Studies[00:03:17]: Genome-Wide Association Studies and Technological Advances[00:04:20]: APOE, Genetic Variants, and Longevity Diversity[00:05:58]: Polygenic Risk Scores and Longevity Prediction[00:08:39]: Sample Sizes and Study Challenges in Longevity Research[00:11:20]: Structural Variants, Mitochondrial DNA, and Data Sharing[00:12:38]: Odds of Reaching Age 100—Historical Perspective[00:15:22]: Healthspan, Compression of Morbidity, and Centenarian Quality of Life[00:17:03]: Supercentenarians and Extreme Longevity[00:21:02]: APOE Mechanisms, Inflammation, and Proteomic Signatures[00:25:16]: Inflammation, Biomarkers, and Healthy Aging[00:29:12]: Nutrition, Diet Balance, and Longevity[00:32:28]: Food Versus Supplements—Practical Dietary Approaches[00:35:02]: Molecular Profiles—Proteomics, Metabolomics, and Lipidomics[00:39:01]: Gut Microbiome, Metabolomics, and Longevity Connections[00:41:42]: Biological Pathways and Omics Insights in Centenarians[00:45:01]: Protein Intake Patterns Across the Lifespan[00:48:23]: Environmental Factors and Longevity[00:50:18]: Physical Activity, Social Networks, and Objective Tracking[00:53:45]: Offspring of Centenarians—Inheritance and Health Outcomes[00:57:05]: Parental Longevity, Gender Differences, and Longevity Bias[01:00:43]: Key Takeaways—Aging as a Positive Process[01:03:25]: Closing Remarks and Episode Wrap-Up[01:03:41]: End of Episode For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram, X

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Terrie Moffitt, University Professor at Duke University. They explore the deep link between mental health, self-control, and the pace of biological aging, showing how early-life mental disorders can shape health decades later.Terrie describes her work with the decades-long Dunedin study, which tracks health from birth through midlife. She explains how people age at different rates, even when born in the same year and place, and how the “pace of aging” can be measured using biomarkers. Terrie shares that fast agers show early signs of physical and cognitive decline, while those with strong self-control tend to experience better health, stronger relationships, and greater financial stability as they grow older.The discussion reveals that treating mental health issues early in life could prevent chronic diseases and slow aging itself. Terrie makes a strong case for taking mental health seriously, both as prevention and as a path to a longer, healthier life. Guest-at-a-Glance💡 Name: Dr. Terrie Moffitt💡 What they do: University Professor💡 Company: Duke University💡 Noteworthy: Known for her research linking early-life mental health to aging, and for leading the Dunedin Study on human development, self-control, and healthspan.💡 Guest Company Website: https://psychiatry.duke.edu/profile/terrie-e-moffitt Episode highlights:[00:00:00]: Introduction[00:00:36]: Overview of the Dunedin Study and Its Origins[00:02:13]: Joining the Dunedin Study: Early Career and Risk-Taking[00:04:35]: Transitioning the Dunedin Study to Aging Research[00:07:52]: Dunedin Cohort Structure and Unique Features[00:10:30]: Biological Samples and Longitudinal Data Collection[00:10:52]: Concept of Pace of Aging vs. Chronological Age[00:13:30]: Measuring and Modeling Pace of Aging[00:14:45]: Validating Pace of Aging: Physical and Cognitive Effects[00:16:27]: Environmental and Generational Controls in the Cohort[00:18:25]: Early Onset of Aging Processes[00:19:49]: Applying Pace of Aging to Other Populations[00:20:59]: Making Pace of Aging Exportable: Epigenetics and Broader Use[00:22:19]: Why the Longevity Industry Needs Pace of Aging Measures[00:24:06]: Economic and Societal Impact of Extending Lifespan[00:27:32]: Challenges in Changing Population Trends and Longevity Solutions[00:28:07]: Testing Anti-Aging Interventions: Need for Surrogate Biomarkers[00:31:28]: Surrogate Biomarkers and Clinical Trial Design for Aging[00:32:04]: Self-Control as a Predictor of Health and Longevity[00:35:11]: Self-Control in Childhood and Its Lifelong Impact[00:36:39]: Mental Disorders and Their Link to Physical Health[00:39:06]: Explaining the Mental Health–Aging Connection[00:42:33]: Prevention Strategies for Healthspan and Mental Health[00:48:59]: Population-Level Changes to Support Longevity[00:56:01]: Rapid-Fire Questions: Behaviors and Habits for Longevity[01:01:29]: Key Takeaway: Mental Health and Lifelong Impact[01:02:44]: Closing Remarks and Episode Wrap-Up For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram, X

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. David Allison, Director of the USDA Children’s Nutrition Research Center at Baylor College of Medicine. Together, they examine what it takes to build public trust in nutrition and longevity science, and why clear, reproducible evidence matters more than ever. David highlights how public perception and scientific rigor can drift apart, especially in fields crowded with strong opinions and shifting trends.David shares sharp insights on weight management, challenging the idea that slow and steady always wins. He explains the “dentistry model” of weight loss, where maintenance matters more than one-time fixes, and explores why most people regain weight without ongoing support. The discussion cuts through assumptions about exercise, protein, and processed foods, showing where animal research aligns, or fails to align, with human studies.Throughout, David pushes for honest communication and transparency in science. He urges listeners to question hype, look past nutrition fads, and recognize the real limits of current evidence. The episode offers practical wisdom for anyone who wants to approach health, nutrition, and longevity with both curiosity and caution. Guest-at-a-Glance💡 Name: Dr. David Allison💡 What he does: Director of the USDA Children’s Nutrition Research Center💡 Company: Baylor College of Medicine💡 Noteworthy: Known for advancing rigor and transparency in obesity and nutrition science, and for challenging assumptions in weight management, protein, and public health research.💡 Where to find him: https://www.linkedin.com/in/david-allison-2917963b/ Episode highlights:[00:00:00]: Introduction[00:00:53]: Background and Credentials[00:02:17]: Importance of Reproducibility and Trust in Science[00:06:50]: Defining Food Noise and Its Measurement[00:10:01]: Biology, Environment, and Psychology of Food Noise[00:13:18]: The Dentistry Model of Weight Management[00:17:40]: Weight Cycling: Human and Mouse Studies[00:21:19]: Long-Term Weight Loss Maintenance and Methods[00:24:13]: Translating Animal and Observational Studies to Human Health[00:29:18]: Exercise, Strength, and Longevity: Human and Animal Evidence[00:34:50]: Exercise, Confounding, and Causal Inference[00:35:57]: Exercise and Healthspan vs. Lifespan[00:37:51]: Designing Experiments for Healthspan and Lifespan[00:40:02]: Mendelian Randomization and Causality in Health Research[00:41:40]: Protein Intake: Trends, Evidence, and Recommendations[00:47:36]: Protein Needs for Special Populations[00:50:57]: High Protein Diets, Amino Acids, and Longevity in Animal Models[00:53:27]: Caloric Restriction and Lifespan Evidence[00:55:22]: Full-Fat Dairy in Dietary Guidelines[00:58:30]: Fermented Dairy and Health Outcomes[01:01:07]: Processed Foods: Scientific and Practical Perspectives[01:04:06]: Overrated Nutrition and Exercise Claims[01:05:37]: Socioeconomic Status and Healthspan[01:07:32]: Skepticism Toward Gut Microbiota Longevity Claims[01:08:05]: Building Public Trust in Science and Closing RemarksFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram, X

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Louise Hecker, Associate Professor of Medicine at Baylor College of Medicine. Together, they dive into Louise’s recent research exploring how psilocybin, the active compound in psychedelic mushrooms, may influence aging biology at the cellular and organismal level.Louise shares the story behind her curiosity about psilocybin, sparked by conversations with a friend and fueled by a lack of scientific answers. She explains how her team overcame regulatory hurdles to study the effects of psilocybin on human cells and aging mice. Their findings showed that psilocybin extended cellular lifespan and reduced hallmarks of aging, such as oxidative stress and DNA damage. In mice, regular dosing improved survival, reversed visible signs of aging, and affected organs beyond the brain.The conversation also covers the challenges of translating these findings into humans, the need for more research on dosing and safety, and the importance of funding in moving this field forward. Louise encourages listeners to stay curious, think beyond established paths, and keep an open mind as new questions and discoveries emerge in the science of aging.Guest-at-a-Glance💡 Name: Dr. Louise Hecker💡 What they do: Associate Professor of Medicine💡 Company: Baylor College of Medicine💡 Guest Company Website: https://www.bcm.edu/people-search/louise-hecker-175346Link to the paper: https://www.nature.com/articles/s41514-025-00244-x Episode highlights:[00:00:00]: Introduction[00:00:18]: Scientific Journey and Focus on Aging[00:01:27]: Transition from Regeneration to Aging Research[00:02:53]: Decline of Regeneration with Age[00:03:43]: Motivation for Studying Psilocybin and Aging[00:04:13]: Initial Curiosity and Literature Review on Psilocybin[00:05:38]: Psilocybin’s Broad Clinical Applications[00:06:19]: Hypothesis: Psilocybin’s Lasting Effects Linked to Aging[00:07:14]: Defining Psilocybin and Its Effects[00:08:25]: Legal Status and Research Barriers[00:09:57]: Resurgence in Psilocybin Research and Regulatory Changes[00:10:40]: Experimental Design: Dosing and Model Selection[00:11:54]: Regulatory Hurdles in Acquiring Psilocybin[00:13:08]: Initiating Experiments and Early Findings[00:14:30]: Cellular Lifespan Extension Results[00:15:17]: Quantifying Cellular Effects and Replication[00:16:23]: Addressing Potential Cancer Concerns[00:17:10]: Hallmarks of Aging and Cellular Markers[00:18:44]: Telomere Length and DNA Protection[00:19:52]: Organ-Specific Effects and Ongoing Research[00:22:05]: Transition to Mouse Studies[00:23:44]: Designing the Mouse Longevity Study[00:26:28]: Results: Survival and Phenotypic Changes in Mice[00:28:36]: Translating Mouse Findings to Humans[00:30:09]: Next Steps: Dosing, Protocols, and Human Relevance[00:32:26]: Omics Profiling and Organ-Specific Protection[00:33:54]: Safety, Risks, and Human Studies[00:35:13]: Comparing Psilocybin to Other Longevity Interventions[00:37:00]: Implementation Challenges and Future Research Directions[00:40:00]: Advice for Biohackers and Caution on Self-Experimentation[00:42:29]: Funding, Research Priorities, and the Future of Psychedelic Research[00:43:58]: Rapid-Fire Questions: Aging Misconceptions and Research Priorities[00:46:11]: Social Connection and Long-Term Health[00:48:50]: Key Takeaways and Closing Thoughts[00:51:26]: Outro and Farewell For science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram,

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Nathan Price, Professor and Co-Director at the Buck Institute for Research on Aging. Together, they explore how systems biology, artificial intelligence, and deep health data are changing the way we approach aging and prevention. Nathan explains why looking at single biomarkers falls short and why a network view of biology gives a clearer path to understanding disease and resilience.Nathan shares how new tools, like genetics, proteomics, and the emerging field of digital twins, can help predict disease risk years in advance and guide more effective, personalized interventions. He also discusses how integrating data from wearables, blood tests, and the microbiome can help people move from reactive medicine to proactive health decisions, allowing for interventions that fit the individual.The conversation highlights the promise and practical limits of current technologies, the trade-offs involved in optimizing health, and the power of AI to accelerate both research and personal health journeys. Nathan makes a strong case for the unique biology each person brings to the table and shows how the tools available today can help anyone take charge of their own healthspan in ways not possible before.Guest-at-a-Glance💡 Name: Nathan Price💡 What he does: Professor and Co-Director of the Center for Human Healthspan💡 Company: Buck Institute for Research on Aging💡 Noteworthy: Known for advancing systems biology and using AI and multi-omics to personalize health and healthspan interventions.💡 Where to find him: https://www.linkedin.com/in/nathandprice Episode highlights:[00:00:00]: Introduction[00:00:49]: Overview of Systems Biology and Its Role in Health[00:03:23]: Systems Biology vs. Reductionist Approaches[00:04:28]: Systems Biology and the Shift from Treatment to Prevention[00:06:29]: Defining Scientific Wellness[00:08:52]: Early Detection of Disease with Omics and AI[00:12:03]: Genetics and Early Risk Prediction[00:15:18]: Polygenic Risk Scores and Population Diversity[00:17:05]: Explaining Polygenic Risk Scores and Their Applications[00:19:01]: Genetics, Lifestyle Interventions, and LDL Cholesterol[00:20:51]: Integrating Multi-Omics Data for Personalized Health[00:23:15]: AI Revolution in Health Data Analysis[00:24:06]: Personalized Health Guidance and AI Agents[00:27:15]: Scaling Scientific Discovery with AI[00:32:23]: AI’s Impact on Healthspan and Personalized Recommendations[00:34:47]: Human-AI Collaboration and Current Limitations[00:36:23]: Accelerating Health Innovation and the Adjacent Possible[00:38:36]: N-of-1 Experiments and Individualized Health Insights[00:40:25]: Aggregating N-of-1 Data and Community Science[00:42:54]: Digital Twins: Building Personalized Biological Models[00:45:05]: Aging as a Network-Level Phenomenon[00:49:43]: Trade-Offs in Aging and Optimizing Health Behaviors[00:52:01]: Accessibility and Adoption of Omics Technologies[00:55:39]: Pyramid of Health Data: From Dense Omics to Passive Measures[00:59:28]: Rapid-Fire Questions and Key TakeawaysFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram, X

In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Ronjon Nag, Adjunct Professor in Genetics at Stanford School of Medicine and President of the R42 Group, for a wide-ranging conversation on how artificial intelligence is reshaping health, medicine, and longevity science.Ronjon makes the case for systems thinking as a necessary framework for understanding aging, arguing that health emerges from complex interactions rather than isolated interventions. He explains how objective data—ranging from blood biomarkers to wearable-derived signals—can be integrated to guide better decisions, cut through conflicting health advice, and personalize interventions. The discussion also explores how AI is becoming a foundational tool, increasingly as ubiquitous as spreadsheets, enabling researchers, clinicians, and individuals to organize, connect, and interpret fragmented health data.The conversation then turns to AI’s expanding role in drug discovery, personalized health insights, and ambitious efforts such as vaccines targeting aging biology. Along the way, Ronjon examines both the promise and the limitations of these approaches, emphasizing why interdisciplinary, data-driven methods—and clear thinking about causation, risk, and uncertainty—are essential for extending healthspan and improving long-term outcomes.Guest-at-a-Glance💡 Name: Dr. Ronjon Nag💡 What he does: Adjunct Professor in Genetics💡 Company: Stanford School of Medicine, and the R42 Group💡 Where to find him:https://www.linkedin.com/in/ronjonnag Episode highlights:[00:00:00]: Introduction[00:06:40]: Lifelong learning and transition to teaching longevity science[00:08:03]: Data science and AI in healthcare decision-making[00:09:54]: Applying financial risk models to medical innovation[00:11:52]: Venture investing in AI and longevity science[00:13:29]: Inventing in aging, eye disease, and AI-driven life sciences[00:15:48]: Impact of AI on the job market and computer science careers[00:16:26]: Systems thinking in health and aging[00:18:06]: Causation, correlation, and evidence in lifestyle science[00:21:00]: Wearables, self-tracking, and feedback loops in health[00:23:31]: Continuous health monitoring and behavioral change[00:25:12]: Blood biomarkers as objective health feedback[00:27:15]: AI’s future impact on biology, aging research, and lifespan[00:29:03]: Language models, context windows, and the nature of AI intelligence[00:32:03]: Empathy, ambition, and programming values into AI[00:34:39]: Guardrails, regulation, and global risks of AI[00:36:41]: Real-world applications of AI in health and longevity today[00:39:13]: Integrating fragmented health data and building digital twins[00:43:23]: Modeling human biology and the future of digital twins[00:46:36]: AI limitations, hallucinations, and learning from mistakes[00:48:14]: Risks and limitations of AI in healthcare and medicine[00:51:13]: AI as collaborator for patients, clinicians, and scientists[00:55:32]: Longevity ventures: vaccine for aging and food-based GLP-1[01:09:38]: Fast food, processed foods, and public health[01:10:03]: Rapid-fire: daily habits, overhyped interventions, and final advice[01:16:59]: Closing remarks and episode wrap-upFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcastConnect with Gil on LinkedIn, Instagram, X